ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

8 links0 made here, not in the record8 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04150965Immuno-Oncology DrugsElotuzumab, Anti-LAG-3 andAnti-TIGITMultiple Myeloma Research ConsPhase 1/Phase 2 · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSMultiple MyelomaThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionRecurrenceThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSElotuzumabEntry “Elotuzumab, pomalidomide, dexa…›Nov 18 · Rule based · ComparatorComparatorPomalidomideEntry “Elotuzumab, pomalidomide, dexa…›Nov 18 · Rule based · ComparatorComparatorDexamethasoneEntry “Elotuzumab, pomalidomide, dexa…›Nov 18 · Rule based · ComparatorComparatorRelatlimabEntry “Anti-LAG-3”, read by our name …›Nov 18 · Rule based · TestedTestedTiragolumabEntry “Anti-TIGIT”, read by our name …›Nov 10 · Claude Opus 5.5 · UnclearNov 18 · Rule based · TestedUnclearRenvistobartEntry “Anti-TIGIT + Pomalidimide + De…›Nov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Tiragolumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Anti-TIGIT”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Unclear
Unclear · 1
Tested · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 10TiragolumabClaude Opus 5.5UnclearCurrent
Nov 18ElotuzumabRule based · role ruleComparatorCurrent
Nov 18PomalidomideRule based · role ruleComparatorCurrent
Nov 18DexamethasoneRule based · role ruleComparatorCurrent
Nov 18RelatlimabRule based · role ruleTestedCurrent
Nov 18TiragolumabRule based · role ruleTestedOverridden
Nov 18RenvistobartRule based · role ruleTestedCurrent
As of nowMultiple MyelomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.